https://pubmed.ncbi.nlm.nih.gov/15483010/
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
Treatment with the immunocytokine EMD 273063 induced immune activation and was associated with reversible clinical toxicities at the MTD of 7.5 mg/m2/d in...
phase iclinical trialof the